Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s SFDA Creates New Regulations And System To Monitor Medical Device Adverse Events

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA has issued new regulations on the reporting and monitoring of adverse events tied to medical devices

You may also be interested in...



Insider Analysis From Asia Pacific Bio Intelligence LLC On China State FDA’s Medical Device Regulations

For China’s State FDA, 2011 was a banner year, with regulations released on good manufacturing practices for both drugs and devices. Multinational companies should take notice and be sure their operations are in compliance.

China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices

BEIJING - An array of regulatory and legal changes covering pharmaceuticals and medical devices in China is likely to be launched or broadened this year, including new GMP guidelines, as the country aims to upgrade supervision of the entire health care sector, according to a leading Chinese lawyer in the area of life sciences-related issues and legislation

China’s MOH-SFDA Merger: Analysts Weigh In

SHANGHAI - China has reorganized the Ministry of Health and put the State FDA under its jurisdiction. The State Council's institutional restructuring scheme was officially approved March 15 at the first session of the 11 National People's Congress held in Beijing

Latest News
See All
UsernamePublicRestriction

Register

SC069970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel